On November 16, 2017, Aurora Cannabis Enterprises Inc., a licensed producer of cannabis for medical purposes located in Alberta, began a voluntary recall of one lot of Sundance Borealis Blend (sativa) dried marijuana under a Type II recall. The affected lot number can be found below.
On November 16, 2017, Aurora Cannabis Enterprises Inc. initiated a voluntary Type II recall for one lot of Sundance Borealis Blend (sativa), sold in 5 g bottles, due to an error in packaging of the product. The delta-9-tetrahydrocannabinol (THC) content identified on the label was higher and the cannabidiol (CBD) content identified on the label were lower than the concentrations present in the product.
For lot 17-118-2042, the products packaged contained a THC value of 16.2% instead of 8.17% THC, and a CBD value of 0.05% instead of 5.91% CBD.
A Type II recall refers to a situation in which the use of, or exposure to a product may cause temporary adverse health consequences, or where the probability of serious adverse health consequences is remote.
Cam Battley,Executive VP at Aurora Cannabis, says the company mislabeled one bottling run, or what he says is about five percent of one lot, which affected about 350 patients. Patients who placed an order for the Sundance Borealis Blend ordered and receiveda product with 8.17% THC and 5.91% CBD, but the labels stated the incorrect cannabinoid levels of 16.2% THC and .05% CBD.
Aurora found the error themselves, and contacted Health Canada. Battley also says Aurora receivedno complaints from patients about the mislabeled product.He says the company will be reaching out to patients over the next few days and offering all affected a full credit.
"It's small, but it's not acceptable," says Battley. "We don't even want to have a small recall. We're going to be judged by how we do this ...
